Israel - hebraico - Ministry of Health

taro international ltd, israel - clozapine - טבליה - clozapine 25 mg - clozapine - clozapine - treatment of schizophrenic patients only in cases who are nonresponsive to conventional therapy.

Israel - hebraico - Ministry of Health

taro international ltd, israel - clozapine - טבליה - clozapine 100 mg - clozapine - clozapine - treatment of schizophrenic patients only in cases who are nonresponsive to conventional therapy.

Israel - hebraico - Ministry of Health

taro international ltd, israel - clozapine - טבליה - clozapine 100 mg - clozapine - clozapine - treatment of schizophrenic patients only in cases who are nonresponsive to conventional therapy.

Israel - hebraico - Ministry of Health

novartis israel ltd - rivastigmine as hydrogen tartrate - קפסולות - rivastigmine as hydrogen tartrate 1.5 mg - rivastigmine - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - hebraico - Ministry of Health

novartis israel ltd - rivastigmine as hydrogen tartrate - קפסולות - rivastigmine as hydrogen tartrate 3 mg - rivastigmine - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - hebraico - Ministry of Health

novartis israel ltd - rivastigmine as hydrogen tartrate - קפסולות - rivastigmine as hydrogen tartrate 4.5 mg - rivastigmine - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementiasymptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - hebraico - Ministry of Health

novartis israel ltd - rivastigmine as hydrogen tartrate - קפסולות - rivastigmine as hydrogen tartrate 6 mg - rivastigmine - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - hebraico - Ministry of Health

lundbeck israel ltd. - memantine hydrochloride - טיפות - memantine hydrochloride 10 mg/g - memantine - memantine - treatment of patient with moderately to severe alzheimer's disease.

Israel - hebraico - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 62.5 mg; proguanil hydrochloride 25 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.malarone is recommended for pediatric patients who weigh over 11 kg.

Israel - hebraico - Ministry of Health

glaxo smith kline (israel) ltd - atovaquone; proguanil hydrochloride - טבליות מצופות פילם - atovaquone 250 mg; proguanil hydrochloride 100 mg - proguanil, combinations - proguanil, combinations - prevention of malaria: for the prophylaxis of p.falciparum malaria, including in areas where chloroquine resistance has been reported. treatment of malaria: for the treatment of acute, uncomplicated p.flaciparum malaria. malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and modiaquine may have unacceptable failure rates, presumably due to drug resistance.